Pre-made Amatuximab benchmark antibody ( Whole mAb, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-020-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody
INN Name	Amatuximab
Target	MSLN
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	4f33:BA:DC:FE:HG/4f3f:BA
95-98% SI Structure	None
Year Proposed	2010
Year Recommended	2011
Companies	Eisai Co Ltd;Morphotek;National Cancer Institute (USA)
Conditions Approved	na
Conditions Active	Mesothelioma
Conditions Discontinued	Pancreatic cancer;Solid tumours
Development Tech	na